marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Iovance Biotherapeutics Financial Ratios 2011-2024 | IOVA
Annual Financial Ratios Iovance Biotherapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.0 | -0.0 | -0.0 | -0.0 | -14.1 | -6.8 | -10.5 | -7.2 | -9.6 | -16.3 | -2.5 | -2.7 | -3.1 |
P/S |
3.5 | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-1.9 | -2.5 | -2.2 | -1.9 | -1.6 | -1.3 | -1.4 | -1.9 | -0.6 | -0.5 | -3.5 | -0.0 | -0.3 |
EV (Enterprise Value) |
85 M | -66.2 M | 80.4 M | 51 M | 2.82 B | 778 M | 833 M | 280 M | 234 M | 153 M | 46.4 M | 20.1 M | 92.6 M |
EBITDA per Share |
-1.91 K | -2.45 K | -2.21 K | -1.89 K | -1.65 | -1.31 | -1.41 | -0.953 | -0.605 | -0.478 | -2.32 | -10.2 | -27.7 |
EV/EBITDA |
-0.2 | -23.2 | -13.5 | -6.0 | -9.0 | -5.2 | -9.4 | -12.7 | -2.0 | -1.7 | -4.0 | ||
PEG |
-0.0 | -0.0 | -0.0 | -0.0 | -0.56 | 0.69 | 0.44 | -0.04 | -0.33 | 0.19 | 0.19 | 0.03 | -0.0 |
P/B |
0.0 | 0.0 | 0.0 | 0.0 | 9.3 | 1.8 | 6.7 | 2.3 | 2.6 | 4.4 | 3.6 | -0.8 | -6.2 |
P/CF |
-0.0 | -0.0 | -0.0 | -0.0 | -16.8 | -8.3 | -12.2 | -11.2 | -13.6 | -19.2 | -17.4 | -3.9 | -12.8 |
ROE % |
-75.95 | -79.24 | -55.05 | -39.54 | -66.08 | -26.51 | -63.28 | -31.69 | -26.59 | -26.84 | -144.18 | 29.22 | 201.03 |
ROA % |
-56.90 | -59.62 | -44.03 | -33.78 | -57.32 | -25.70 | -59.25 | -30.77 | -26.18 | -25.88 | -127.71 | -11245.43 | -4520.19 |
ROCE % |
-68.74 | -69.67 | -49.80 | -36.71 | -67.70 | -27.50 | -63.84 | -32.13 | -26.78 | -26.85 | -128.61 | 71.85 | 164.76 |
Current Ratio |
4.0 | 4.0 | 5.0 | 6.9 | 8.1 | 33.0 | 15.1 | 34.1 | 63.8 | 27.1 | 8.7 | 0.0 | 0.0 |
DSO |
23.2 | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
176.0 | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
1013.5 | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
199.2 | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
-814.3 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Iovance Biotherapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.28 | -0.34 | -0.42 | - | -0.46 | -0.47 | -0.5 | - | -0.63 | -0.63 | -0.58 | - | -0.55 | -0.53 | -0.51 | -0.47 | -0.4 | -0.47 | -0.55 | -0.5 | -0.4 | -0.38 | -0.3 | -0.27 | -0.36 | -0.34 | -0.31 | -0.36 | -0.35 | -0.37 | -0.33 | -0.25 | -1.15 | -0.23 | -0.14 | -0.17 | -0.16 | -0.14 | -0.14 | -0.17 | -0.11 | -0.09 | -0.11 | - | -0.66 | -4.19 | -1.28 | - | -0.86 | - | 7.39 | - | -0.07 | -0.15 | -0.01 |
EBITDA per Share |
-284 | -347 | -0.43 | - | -470 | -477 | -0.51 | - | -0.62 | -0.62 | -0.57 | - | -0.54 | -528 | -510 | - | -397 | -474 | -557 | - | -409 | -401 | -322 | - | -361 | -343 | -316 | - | -342 | -370 | -332 | - | -309 | -219 | -139 | - | -0.15 | -0.13 | -0.14 | - | -0.1 | -0.09 | -0.11 | - | -0.66 | -1.25 | -0.86 | - | -2.07 | -2.1 | -4.01 | - | -0.07 | -0.13 | -0.01 |
ROE % |
-56.93 | -63.00 | -68.78 | -51.39 | -76.69 | -85.11 | -87.72 | -62.91 | -75.25 | -62.28 | -52.19 | -34.91 | -45.33 | -41.92 | -40.59 | -39.54 | -50.38 | -58.01 | -64.32 | -66.08 | -51.80 | -42.51 | -33.18 | -26.51 | -37.29 | -45.26 | -54.75 | -63.28 | -54.91 | -80.55 | -71.41 | -61.32 | -59.95 | -26.43 | -25.62 | -26.59 | -28.92 | -28.31 | -26.89 | -26.84 | -69.91 | -116.64 | -131.42 | -78.87 | -72.92 | -13.52 | 8.85 | 59.84 | 105.37 | 144.94 | 227.80 | 135.69 | 45.52 | 85.75 | 4.42 |
ROA % |
-44.83 | -49.75 | -53.75 | -40.43 | -58.68 | -63.58 | -62.58 | -44.37 | -54.77 | -33.85 | -43.38 | -29.98 | -38.88 | -36.11 | -34.78 | -33.78 | -43.32 | -50.06 | -55.66 | -57.32 | -45.65 | -38.33 | -30.91 | -25.70 | -35.57 | -42.79 | -51.46 | -59.25 | -51.74 | -77.17 | -68.85 | -59.54 | -58.33 | -25.87 | -25.17 | -26.18 | -28.27 | -27.52 | -26.03 | -25.88 | -63.22 | -104.09 | -116.80 | -69.87 | -2361.02 | -4604.82 | -5700.29 | -23030.15 | -24053.76 | -22786.21 | -23601.57 | -3050.95 | -1023.61 | -1928.07 | -99.27 |
ROCE % |
-52.42 | -57.76 | -62.52 | -47.04 | -68.55 | -74.52 | -79.16 | -57.31 | -68.59 | -58.37 | -47.55 | -32.43 | -40.69 | -37.67 | -36.31 | -27.10 | -43.99 | -52.62 | -60.12 | -46.39 | -53.91 | -44.54 | -34.85 | -20.01 | -35.36 | -43.21 | -52.69 | -45.92 | -57.29 | -53.30 | -44.12 | -22.60 | -29.94 | -25.92 | -25.09 | -18.63 | -24.88 | -23.78 | -22.30 | -15.99 | -69.44 | -116.64 | -117.78 | -63.30 | -48.92 | 18.91 | 39.30 | 56.63 | 102.12 | 133.23 | 201.32 | 133.27 | 45.49 | 82.63 | 5.15 |
Current Ratio |
4.5 | 4.9 | 4.6 | 4.0 | 4.8 | 4.2 | 5.2 | 4.0 | 3.6 | - | 4.7 | 5.0 | 6.3 | 7.9 | 7.3 | 6.9 | 6.9 | 6.9 | 6.9 | 7.5 | 7.5 | 7.5 | 7.5 | 32.9 | 32.9 | 32.9 | 32.9 | 15.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
68.1 | 46.7 | 24.6 | - | - | 6.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
76.1 | 66.1 | 175.9 | - | 198.8 | 216.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
59.7 | 67.1 | 369.6 | - | 530.2 | 1396.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
144.2 | 112.8 | 200.4 | - | 198.8 | 222.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
84.5 | 45.8 | -169.2 | - | -331.3 | -1173.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency